Effect of KYG0395 on Primary Dysmenorrhea
Summary
The purpose of this study is to further assess the efficacy, safety and dose-response of KYG0395 in the treatment of primary dysmenorrhea.
Timeline
- Start
- 2012-05
- Primary completion
- 2015-07
- Completion
- 2015-07
Outcome
Mixed primary results
registry analysis (unspecified test); KYG0395 (High Dose Group) vs KYG0395 (Lower Dose Group) vs Placebo; p >0.05; Mixed Models Analysis NCT01588236 ↗
registry analysis (unspecified test); KYG0395 (High Dose Group) vs KYG0395 (Lower Dose Group) vs Placebo; p <0.01; Mixed Models Analysis NCT01588236 ↗
registry LEAST_SQUARES_MEAN KYG0395 (High Dose Group): -22.8 (Standard Error 2.93) unit of a scale NCT01588236 ↗
registry analysis (unspecified test); KYG0395 (High Dose Group) vs KYG0395 (Lower Dose Group) vs Placebo; p <0.05; Mixed Models Analysis NCT01588236 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KYG0395 | Unknown | — | — |